HCPCS Level II code J2182 denotes the injectable biologic mepolizumab in 1 mg units. Mepolizumab is an anti-IL-5 monoclonal antibody used in the management of eosinophilic-driven conditions; its billing via unit-based HCPCS codes supports dosing, inventory tracking, and payer reimbursement across outpatient and infusion settings. Nationally, accurate reporting of J2182 matters for clinical continuity, drug utilization monitoring, and consistent claims processing for infused or injected biologic therapies.

This publication covers payer policies and coverage context for Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find benchmarks for unit reporting and common billing patterns, summaries of relevant policy features affecting coverage decisions, and discussion of clinical context tied to injectable biologic administration. The report also outlines typical sites of service and the service type tied to J2182, identifies common modifiers used in practice, and flags data gaps where input information is not provided.

Intended for revenue cycle leaders, clinicians, and policy analysts, this summary provides a concise reference to the code’s clinical meaning, payer scope, and the operational considerations that influence billing and claims adjudication for mepolizumab when reported by the unit.